<div class="bk-sec"><div><table class="default-table glossary"><tbody>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>FEV<sub>1</sub>
</td>
<td>Forced expiratory volume in 1 s</td>
</tr>
<tr>
<td>FF</td>
<td>Fluticasone furoate</td>
</tr>
<tr>
<td>FP</td>
<td>Fluticasone propionate</td>
</tr>
<tr>
<td>GOLD</td>
<td>Global Initiative for Chronic Obstructive Lung Disease</td>
</tr>
<tr>
<td>HR</td>
<td>Hazard ratio</td>
</tr>
<tr>
<td>ICS</td>
<td>Inhaled corticosteroid</td>
</tr>
<tr>
<td>INSPIRE</td>
<td>Investigating New Standards for Prophylaxis in Reduction of Exacerbations</td>
</tr>
<tr>
<td>LABA</td>
<td>Long-acting β<sub>2</sub>-agonists</td>
</tr>
<tr>
<td>RR</td>
<td>Rate ratio</td>
</tr>
<tr>
<td>SFC</td>
<td>Salmeterol/fluticasone propionate combination</td>
</tr>
<tr>
<td>SUMMIT</td>
<td>Study to Understand Mortality and MorbidITy</td>
</tr>
<tr>
<td>TORCH</td>
<td>Towards a Revolution in COPD Health</td>
</tr>
<tr>
<td>UPLIFT®</td>
<td>Understanding Potential Long-term Impacts on Function with Tiotropium</td>
</tr>
<tr>
<td>VI</td>
<td>Vilanterol</td>
</tr>
</tbody></table></div></div>